Abstract: The quantitative evaluation of biomarker-probe activity is disclosed. In certain embodiments, the biomarker-probe activity may be quantified and analyzed using biodistributions generated using a model. In some embodiments, such biodistributions may be used to generate simulated images from which quantitative thresholds may be derived. In some embodiments, the quantitative thresholds may be used to analyze the biodistributions.

Abstract: The quantitative evaluation of biomarker-probe activity is disclosed. In certain embodiments, the biomarker-probe activity may be quantified and analyzed using biodistributions generated using a model. In some embodiments, such biodistributions may be used to generate simulated images from which quantitative thresholds may be derived. In some embodiments, the quantitative thresholds may be used to analyze the biodistributions.

Abstract: In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I wherein R1 is independently at each occurrence a hydroxy group, a C1-C3hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3hydroxyalkyl group; and wherein Q is a charge balancing counterion. Also provided is a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement I.

Abstract: In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3 hydroxyalkyl group; and wherein Q is a charge balancing counterion. Also provided is a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement I.

Abstract: The quantitative evaluation of biomarker-probe activity is disclosed. In certain embodiments, the biomarker-probe activity may be quantified and analyzed using biodistributions generated using a model. In some embodiments, such biodistributions may be used to generate simulated images from which quantitative thresholds may be derived. In some embodiments, the quantitative thresholds may be used to analyze the biodistributions.